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Idiopathic T-CD4 lymphocytopenia (ICL) is a rare and heterogeneous syndrome
characterized by opportunistic infections due to reduced CD4 T-lymphocytes (<300
cells/µl or <20% T-cells) in the absence of HIV infection and other primary causes of
lymphopenia. Molecular testing of ICL has revealed defects in genes not specific to
CD4 T-cells, with pleiotropic effects on other cell types. Here we report for the first
time an absolute CD4 lymphocytopenia (<0.01 CD4+ T-cells/µl) due to an autosomal
recessive CD4 gene mutation that completely abrogates CD4 protein expression on
the surface membrane of T-cells, monocytes, and dendritic cells. A 45-year-old female
born to consanguineous parents consulted because of exuberant, relapsing, and
treatment-refractory warts on her hands and feet since the age of 10 years, in the
absence of other recurrent infections or symptoms. Serological studies were negative
for severe infections, including HIV 1/2, HTLV-1, and syphilis, but positive for CMV and
EBV. Blood analysis showed the absence of CD4+ T-cells (<0.01%) with repeatedly
increased counts of B-cells, naïve CD8+ T-lymphocytes, and particularly, CD4/CD8
double-negative (DN) TCRαβ+ TCRγδ− T-cells (30% of T-cells; 400 cells/µl). Flow
cytometric staining of CD4 using monoclonal antibodies directed against five different
epitopes, located in two different domains of the protein, confirmed no cell surface
membrane or intracytoplasmic expression of CD4 on T-cells, monocytes, and dendritic
cells but normal soluble CD4 plasma levels. DN T-cells showed a phenotypic and
functional profile similar to normal CD4+ T-cells as regards expression of maturation
markers, T-helper and T-regulatory chemokine receptors, TCRvβ repertoire, and in vitro
cytokine production against polyclonal and antigen-specific stimuli. Sequencing of the
Fernandes et al. Complete Multilineage CD4 Expression Defect
CD4 gene revealed a homozygous (splicing) mutation affecting the last bp on intron 7–8,
leading to deletion of the juxtamembrane and intracellular domains of the protein and
complete abrogation of CD4 expression on the cell membrane. These findings support
previous studies in CD4 KO mice suggesting that surrogate DN helper and regulatory
T-cells capable of supporting antigen-specific immune responses are produced in the
absence of CD4 signaling and point out the need for better understanding the role of
CD4 on thymic selection and the immune response.
Keywords: CD4, warts, double-negative T-cells (DNTs), CD4 lymphopenia, idiopathic CD4 lymphocytopenia
BACKGROUND
CD4 is a monomeric type I transmembrane glycoprotein
consisting of four immunoglobulin-like extracellular domains
connected by a short stalk to a transmembrane domain and
a short cytoplasmic tail (1–4). Although rare polymorphisms
have been described in humans that suppress reactivity with
the anti-CD4 OKT4 antibody clone (5, 6), comparison of CD4
sequences from different animal species indicates that the basic
structure of this molecule was highly preserved during evolution
for more than 400 million years (7). The CD4 molecule is mostly
known because it has long been used to define helper T-cells and,
more recently, regulatory T-cells (Tregs). These represent two
functionally unique T-cell populations responsible for driving
humoral and cytotoxic responses through production of different
cytokine profiles (8, 9) and suppressing the immune response
(10), respectively. In addition, lower CD4 expression is also
detected on antigen-presenting cells such as monocytes and
dendritic cells (DCs) (11) and onmegakaryocytic precursors (12).
Multiple studies have demonstrated that CD4 serves as
a co-receptor during T-cell receptor (TCR) recognition of
major histocompatibility complex MHC/HLA class II–associated
peptides (1–3). Binding of the membrane-distal D1 domain
of CD4 to non-polymorphic residues of MHC/HLA class II
molecules provides a more potent stimulus for the T-cell than
simply ligating the TCR alone (1–3). Thus, ligation of CD4
to MHC/HLA class II has been shown to induce positive
selection of helper T-cells during thymic differentiation (4)
and supports activation of helper T-cells and Tregs in blood
and other lymphoid and non-lymphoid tissues (1–3). However,
CD4–MHC/HLA class II affinity is low, leading to weak
binding between the two proteins (2, 3). As a consequence,
other molecules are required for productive interactions with
downstream effects. In fact, it has been confirmed in murine
models that differentiation of helper T-cells can occur in
the absence of CD4 expression, suggesting that signaling via
this co-receptor might be dispensable (13, 14). Thus, in CD4
knock-out (KO) mice, an expanded subpopulation of CD4/CD8
double-negative (DN) TCRαβ+ T-cells with T-helper ability
is generated at abnormally high numbers, which functionally
replace conventional CD4+ T-cells (13, 14).
A limited number of cases (n≈ 100) of persistent CD4+ T-cell
lymphopenia in the absence of human immunodeficiency virus
1 (HIV 1) infection have been reported so far. Of note, none
of these patients have been associated with a specific defect of
CD4 expression. Most of the cases display clinical manifestations
that are characteristic of combined immunodeficiencies (15, 16).
Although in the majority of the cases, the genetic etiology
of Idiopathic T-CD4 lymphocytopenia (ICL) has not been
investigated, preliminary molecular genetic studies in 20 patients
suggest that, at least in some patients, there are mutations in
several genes other than CD4 (i.e., RAG1, DOCK8, MAGT1),
with pleotropic effects not restricted to CD4+ T-cells (17–
19). Altogether, these findings suggest that the clinical and
immunological alterations reported in ICL are most likely
associated with a helper T-cell defect potentially combined with
defects on other cell lineages, rather than with a lack of expression
of the CD4 molecule.
Here we report for the first time in human a selective CD4
molecule deficiency associated with a homozygous autosomal
recessive mutation in the CD4 gene that completely abrogates
expression of the CD4 protein. The immunological and clinical
features of this case support previous studies on CD4 KO mice
suggesting that, although the immune response is affected in
these cases, surrogate CD4-negative CD8-negative helper T-cells
and Tregs can be produced in the absence of CD4 signaling,
which are capable of replacing most of the functional roles of
CD4+ T-cells.
CASE PRESENTATION
A 45-year-old Caucasian female born to first-cousin parents, with
two healthy children and without any relevant family history
record of prior diseases, was seen at the service of Dermatology
(University of Coimbra, Coimbra, Portugal) in March 2014
because of persistent extensive, skin-colored, exuberant, and
disfiguring warts in both feet and hands since the age of 10 years
(Figure 1). Warts were refractory to treatment with keratolytic
agents, cryosurgery, and excision, with minor improvement after
treatment with acitretin in association with topical 50% urea
cream. Apart from this, the patient did not describe recurrent
infection-related episodes or diseases, except for past medical
history of measles and mumps during her infancy and varicella
infection during her first pregnancy, which all resolved without
complications. Of note, such past history of infections is not
rare among the patient age-matched Portuguese population since
vaccination for these diseases was introduced in the Portuguese
national vaccination program years after she was born (1969): in
1974 for measles, in 1987 for mumps, and in 2004 for varicella
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FIGURE 1 | Photographs of warts present in the patient’s feet.
(20–22). In fact, outbreaks of measles and mumps have been
reported in Portugal until the late 80s to mid-90s, with peaks of
>10,000 cases per year (20, 21).
In addition, she referred allergic rhino-conjunctivitis treated
with cetirizine and fluticasone, and chronic polyarthralgias
in the absence of impaired functionality. Serological studies
were negative for (severe) infections, including HIV 1/2,
HTLV-1, and syphilis. In turn, she showed IgG antibodies
for ubiquitous pathogens including CMV >250 arbitrary
units (AU/ml) (positive threshold >6AU/ml) and Epstein–
Barr virus VCA = 192 U/ml (positive threshold >20 U/ml)
and EBNA = 24 U/ml (positive threshold >20 U/ml) in the
absence of serum IgM antibodies for these pathogens (0.06
AU/ml; positive threshold >6AU/ml). Slightly increased serum
IgG levels (IgG: 1,430 mg/dl), associated with normal IgA
(278 mg/dl), IgM (67 mg/dl), C3 (1.4 g/L), C4 (0.33 g/L),
and C1 inhibitor (0.318 g/L) serum levels, were detected.
In addition, anti-neutrophil and anti–double-strand DNA
autoantibodies were negative, while antinuclear autoantibodies
were weakly positive. Screening for immunological alterations
by flow cytometry (Supplementary Material) (23–25) using
the EuroFlow Primary Immunodeficiency Orientation Tube
(PIDOT) (26, 27) showed an absolute defect of CD4-expressing
T-cells (<0.01 cells/µl), with normal total T-cell, CD8+
TCRγδ− T-cell, and NK-cell (absolute) numbers, associated with
consistently increased B-cell counts vs. age-matched normal
reference values. Importantly, (TCRαβ+ TCRγδ−) DN T-
cells were significantly expanded (Table 1). Signs/symptoms
associated with primary immunodeficiency other than persistent
warts in the feet and hands were not observed either at
presentation or during the subsequently 5-year follow-up period.
Of note, peripheral blood (PB) monocytes and DCs showed no
cell surface expression of CD4.
LABORATORY INVESTIGATIONS AND
DIAGNOSTIC TESTS
Expression of CD4 on T-Cells, Monocytes,
and DCs
Since rare CD4 polymorphisms that abrogate reactivity of some
monoclonal antibodies (MoAbs) with the CD4 molecule have
been described (5, 6), CD4 expression was evaluated using
eight different MoAb clones. These eight CD4 MoAb clones
were directed against five different epitopes located in two
distinct domains of the CD4 protein (Supplementary Material;
Figure 2A), as confirmed in competitive staining inhibition
experiments (data not shown), in line with previous data in the
literature (32–34). Detectable levels of either surface membrane
(sm) or intracytoplasmic (cy) CD4 expression were observed
in none of the cell lineages that usually express this protein in
blood of healthy controls, such as T-cells, monocytes, and DCs
(Figure 2B). A lack of CD4 expression was confirmed for both
classical T-cells and invariant MAIT and iNKT cells (data not
shown). In contrast, the expression of other molecules previously
associated with CD4 lymphopenia, such as CD3 and HLA-DR
(35), was normal and comparable to that observed in healthy
donors (data not shown). Besides no cellular CD4 protein being
detected, normal soluble CD4 levels in plasma were observed
in the patient using an ELISA assay with a pair of antibodies
directed against the extracellular domains of CD4 (amino acids
26–390; Table 2).
CD4 Gene DNA and cDNA Sequencing
CD4 gene sequencing of patient DNA revealed an isolated
homozygous mutation (Figure 3; Supplementary Table 1) in the
last bp of the 7–8 intron (NC_000012.12: g6818420 G>A),
corresponding to the juxtamembrane domain of the CD4
protein. This alteration was considered by the Variant Effect
Predictor Tool (VEP) (36) as a splice acceptor variant with
a high impact on CD4 protein transcription. No wild type
CD4 DNA sequence was detected based on the analysis of
the sequence of the amplicon products obtained after PCR
amplification of DNA from the patient. Instead, two truncated
forms of CD4 RNA/cDNA were detected. Both truncated forms
of CD4 RNA presented with a frameshift deletion starting at
the juxtamembrane region at the first bp of exon 8 and a
premature stop codon associated with a truncated protein with
normal extracellular domains in the absence of the anchoring
domain to themembrane (Figure 3). The first frameshift deletion
(NM_000616: c.1157_1278del) consisted of a complete deletion
of exon 8 (122 pb), resulting in a 399-amino-acid protein. In
turn, the second frameshift deletion produced a 430-amino-
acid protein because of (only) a 29 bp deletion (NM_000616:
c.1157_1185del) (Figure 3) that ended just before a 5 bp
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TABLE 1 | Distribution of distinct populations of innate immune cells T- and B-
lymphocytes in the CD4null patient here reported compared to age-matched
reference values.
Leucocyte subsets Patient Age reference values
T-cells 1,700 ± 733 (743–2,379)
CD4+ CD8− TCRγδ− T-cells 0 ± 0 (501–1,654)
Naïve 0 ± 0 (83–1,057)
Central memory/transitional
memory
0 ± 0 (235–784)
Effector memory 0 ± 0 (25–208)
Terminally differentiated 0 ± 0 (0–663)
CD4− CD8+ TCRγδ− T-cells 902 ± 367 (133–1,432)
Naïve 556 ± 226 (29–386)
Central memory/transitional
memory
217 ± 98 (59–453)
Effector memory CD27− 105 ± 26 (6–323)
Effector CD27dim 4 ± 6 (7–457)
Terminally differentiated 33 ± 14 (0–500)
TCRγδ+ T-cells 238 ± 96 (7–231)























NK-cells 603 ± 134 (150–672)
Classical monocytes 610 ± 258 (343–1,104)
CD62L+ cMo 249 (2–731)*
CD62L− cMo 220 (19–473)
Non-classical monocytes (CD16++) 169 ± 102 (26–141)
iMo (CD14+/CD16++) 21 (0–89)
Late ncMo (CD14−/CD16++) 120 (0–160)
SLAN− Late ncMo 96 (0–155)
SLAN+ Late ncMo 24 (0–52)
Plasmacytoid DCs 6 ± 3 (4–29)
Neutrophils 3,872 ± 787 (1,800–6,782)
Eosinophils 213 ± 64 (0–648)
Basophils 62 ± 15 (10–64)
B-cells 517 ± 241 (48–413)
Immature B-cells 7.5 ± 2.1 (0.8–23)
Naïve B-cells 394 ± 155 (26–244)
CD21+ 388 ± 151 (24–372)
CD21− 5.5 ± 3.5 (0.3–31)
Memory B-cells 209 ± 77 (25–173)
CD27+ 194 ± 71 (19–160)
CD27− 15 ± 5.7 (1.4–17)
CD21+ 201 ± 76 (16–144)
CD21− 8.0 ± 1.4 (2.8–33)
IgM++D+ 82 ± 38 (12–114)
IgG1+ 42 ± 11 (2.8–30)
(Continued)
TABLE 1 | Continued
Leucocyte subsets Patient Age reference values
IgG2+ 17 ± 3.5 (0.6–14)
IgG3+ 9.0 ± 4.2 (0.7–6)
IgG4+ 0.8 (<0.01–4.1)
IgA1+ 44 ± 18 (2.5–27)
IgA2+ 13 ± 1.4 (0.4–14)
Only IgD+ 0.7 ± 1.0 (<0.01–0.9)








Only IgD+ <0.01 (<0.01–0.1)
Results expressed as (mean± standard deviation) absolute cell counts perµl of peripheral
blood, obtained from repeated analysis performed during the last 5 years following
diagnosis. Normal reference values expressed asminimum andmaximum of age-matched
healthy donors (40–59 years) based on previously published data (20, 21, 26, 28) are
also shown between brackets (). Populations that showed abnormal absolute numbers
compared to age-reference values are depicted in bold. *Reference values obtained from
CD4+ CD8− TCRγδ− T-cells of age-matched healthy donors. DNT, double-negative T-cell;
Tregs, regulatory T-cells; TFH, follicular helper T-cells; DCs, dendritic cells; cMo, classical
monocytes; iMo, intermediate monocytes; ncMo, non-classical monocytes.
combination (TGCAG), homologous to the sequence observed
at the end of the 7–8 intron (Figure 3).
In order to investigate the origin of the mutation, DNA
from four first-degree patient relatives (all asymptomatic) was
also analyzed. Thus, the mutation identified in the patient
(NC_000012.12: g6818420 G>A) was also found in heterozygosis
in DNA from each of her two children and each of her parents.
In contrast, her brother’s DNA only showed wild type CD4
gene sequences. Further cDNA sequencing from her children
and her parents revealed two CD4 mRNA sequences, one
carrying the large deletion observed in the patient (NM_000616:
c.1156_1278del) and another with the unmutated (wild type)
CD4 allele sequence (Figure 3). These results are fully consistent
with a germinal mutation in the patient inherited from her
parents and transmitted to her children. In contrast, in the
patient’s brother, both alleles were found to be wild type.
Analysis of CD4 protein levels by flow cytometry confirmed
that, although normal CD4+ T-cell counts were observed in
the patient’s children and parents (Table 3), the amount of
expression of the CD4 protein on CD4+ T-cells, monocytes, and
pDCs was reduced to around half when compared to healthy
controls (n = 3) and the patient’s brother, stained in parallel
(Supplementary Table 2).
Immunophenotypic and Functional
Characterization of Expanded CD4/CD8
DN T-Cells
As described above, a lack of CD4 expression on patient T-cells
was associated with abnormally expanded DN TCRγδ− TCRαβ+
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FIGURE 2 | Schematic representation of the CD4 protein molecule (A) and CD4 surface membrane expression in the patient’s (vs. healthy donor) blood CD8−
TCRγδ− T-cells, monocytes, and dendritic cells (B). Panel (A) shows a schematic representation of the CD4 protein molecule including the localization of epitopes
identified by the distinct antibody clones used in this study (29–31). Amino acid positions that conform each domain are indicated between brackets. Black arrows
depict the domain that contains those epitopes that the antibody clones are directed to. Panel (B) shows CD4 surface membrane expression levels for CD8− TCRγδ−
T-cells, monocytes, and dendritic cells for the different anti-CD4 antibody clones tested in the patient (black histogram) compared to a representative healthy donor
(gray histogram) and an isotype control (red dash line), and the staining for a negative population (CD8+ T-cells) in the patient (green line) and the healthy control (blue
line). DCs, dendritic cells.
T-cell counts in PB (>30% of all T-cells; Table 1), compared to
age-matched normal reference values (26, 27). Based on CD27,
CD45RA, and CCR7 expression, these DN T-cells showed a
similar distribution per maturation stage to that of CD4+ T-cells
from age-matched healthy controls, both in relative and absolute
numbers: (i) naïve: 27% and 240 cells/µ (6–66% and 83–676
cells/µl), (ii) central memory: 66% and 587 cells/µl (18–71% and
235–589 cells/µl), and (iii) effector memory: 7% and 62 cells/µl
(2–66% and 14–221 cells/µl) (26, 27). In addition, expanded DN
T-cells showed a polyclonal TCRVβ repertoire with a distribution
per TCR family evaluated, fully consistent with reference TCRVβ
repertoire values observed in HLA class II–restricted CD4+
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TABLE 2 | Soluble CD4 plasma levels detected in the patient and her children





Healthy donor 1 11.7
Healthy donor 2 9.20
T-cells from healthy donors (37) (Supplementary Figure 1).
More extended phenotypic analysis of central/effector memory
DN T-cells from the patient showed Treg and Th surrogate
marker expression profiles for Tregs, TFH, Th1, Th2, Th17,
and Th1/Th17 CD4+ helper T-cell to be present at frequencies
similar to those observed for normal CD4+ T-cells (Table 1) from
age-matched healthy donors (Botafogo et al., submitted).
Short-term in vitro stimulation, for 4 and 6 h, showed that
the expanded DN T-cells were capable of producing cytokines
from the main Th patterns (e.g., IFNγ, IL-4/IL-5, and IL-17A/IL-
17F) at frequencies similar to CD4+ helper T-cells from age-
matched healthy controls, when either polyclonal (i.e., PMA)
or antigen-specific (i.e., CMV) stimuli that required antigen
presentation were used (Table 4). In contrast, the percentage of
DN T-cells expressing markers of cytotoxic T-cells (cyGranzyme
B or cyPerforin) was decreased below<1% (normal age-matched
range of <1–21% of DN T-cells).
Immunophenotypic and Functional
Evaluation of Cytotoxic, Humoral, and
Innate Immune Cells and Immune
Responses
Normal total CD8+ T-cell, TCRγδ+ T-cell, and NK-cell counts
were found in the patient blood, although the latter two were
increased in some of the monitoring time points tested during
the 5-year follow-up period. In contrast, consistently increased
naïve CD8+ T-cell counts (Table 1) vs. age-matched reference
values (26, 27), associated with normal central and effector
memory CD8+ T-cell numbers, were found in the patient’s
blood at different time points. Expression of cytolytic enzymes
(cyGranzyme B and cyPerforin) was detected in CD8+ T-cells
(13 and 9% of CD8+ T-cells) and NK-cells (>99%) at normal
values (15–65% and 10–53% of CD8+ T-cells, respectively;>99%
of NK-cells). In addition, CD8+ TCRαβ+ T-cells also showed a
normal polyclonal TCRVβ repertoire (vs. normal age-matched
reference values, shown in Supplementary Figure 1) (37) and
a normal cytokine production profile in response to PMA and
CMV (Table 4) (29).
Detailed dissection of the PB B-cell compartment from the
patient showed persistently increased total B-cell counts due to
increased naïve (CD21+) B-cells, IgG1−3 and IgA1 memory B-
cells, and IgA1 plasmablasts, with normal immature/transitional
B-cell numbers (Table 1) (28, 38), in line with the observed
higher serum IgG levels.
Analysis of circulating PB monocytes based on expression of
CD14 (LPS receptor) and CD16 (low-affinity Fc IgG receptor)
showed normal absolute counts for all subsets (Table 1) (39),
including: (1) CD14+ CD16− classical monocytes (cMo), (2)
CD14+ CD16+ intermediate monocytes (iMo), and (3) CD14−
CD16+ non-classical monocytes (ncMo). Further dissection of
cMo and ncMo based on the expression of the CD62L and
SLAN selectins, respectively, did not show significant differences
vs. normal age-matched reference values (39). In addition,
CD4-negative monocytes and DCs were capable of producing
cytokines at frequencies similar to their CD4+ counterparts from
age-matched healthy control blood, after stimulation with LPS
and γ-IFN (Supplementary Table 3) (40).
Clinical Records and Immunophenotypic
and Functional Features of Immune Cells
of Patient Relatives
All patient relatives were completely asymptomatic, and they
have no past history of recurrent infections or cancer. The
father of the patient has had type diabetes since he was 45
years old. They do not have other records of autoimmunity.
No significant consistent alterations were found as regards the
distribution of immune cell subsets (n > 50) in the blood
of the relatives of the patient, once compared to age-matched
reference values, except for a slight increase in IgG1, IgG4,
and IgD-only memory B-cells in the patient’s daughter (Table 3
and Supplementary Tables 4, 5). In addition, a normal TCRvβ
repertoire distribution (data not shown) together with normal
in vitro cytokine production profiles in response to both PMA
and CMV (Table 4) were observed among the patient’s parents,
children, and brother.
DISCUSSION
Here we describe for the first time in the literature a patient
carrying an inherited homozygous autosomal recessive mutation
in the CD4 gene leading to complete absence of CD4 expression
on the surface membrane of blood T-cells, monocytes, and DCs.
This was associated with a relatively mild clinical phenotype
consisting of extensive (treatment-refractory) warts in both feet
and hands. Lack of CD4 expression was confirmed by flow
cytometry on both the surface and cytoplasm of T-cells (<0.01
CD4+ cells/µl) and other CD4+ myeloid immune innate cells
(<0.01 CD4+ monocytes and DCs/µl). Despite this, normal
soluble CD4 protein levels were found in plasma by ELISA. Rare
CD4 polymorphisms that abrogate reactivity of some MoAbs
with the CD4 molecule have been described (5, 6). However,
in our patient, we demonstrated a lack of reactivity for eight
different MoAb clones directed against five distinct epitopes
located in two different domains of the CD4 protein, which
confirms that the lack of CD4 expression was not due to any
previously described single-nucleotide polymorphism in the CD4
gene (5, 6).
In contrast, CD4 gene sequencing of patient DNA revealed
that the lack of CD4 expression at the cell surface membrane
was associated with a homozygous mutation of the CD4 gene in
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FIGURE 3 | Nucleotide sequences of CD4 PCR products for the regions of interest and their localization in the CD4 gene. Panel (A) shows a representative sequence
of CD4 focused on the region of interest. Gray underlining shows the nucleotide sequence affected by the major deletion (NM_000616: r.1157_1278del), and orange
top line shows the nucleotide sequence affected by the minor deletion (NM_000616: r.1157_1185del). Panels (B,C) show mRNA electropherograms obtained from
(Continued)
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FIGURE 3 | analysis of the minor (NM_000616: r.1157_1185del) and major (NM_000616: r.1157_1278del) deletions detected in the patient’s CD4 cDNA, respectively,
and the patient’s relatives (C). Panels (D–F) show genomic DNA electropherograms from: (D), wild type CD4 gene; (E), patient’s homozygous mutated CD4 gene;
and (F), heterozygous mutated CD4 gene from the patient’s parents and children. Panels (G,H) display a schematic representation of the localization in wild type CD4
protein of the mutated (green) nucleotide bases and the deleted (red) amino acid sequences, including the minor (G) and major (H) deletions, observed in the
truncated CD4 cDNA molecules detected in the CD4null patient here reported. Panel (I) shows the family pedigree (men are represented as squares and women as
circles), including the key clinical manifestations and, between brackets, the results of CD4 DNA analysis in a coded/graphic format: half-shaded circles and squares,
heterozygous DNA; fully shaded circles and squares, homozygous mutated DNA; and unshaded circles and squares, wild type DNA.
TABLE 3 | PB distribution of distinct populations of innate immune cells T- and B-lymphocytes in the patient relatives as analyzed with the EuroFlow Primary











T-cells 1,470 (564–2,935) 1,159 (564–2,935) 1,561 (636–3,030) 1,910 (636–3,030) 1,056 (564–2,935)
CD4+ 663 (207–1,900) 726 (207–1,900) 900 (345–1,474) 1,293 (345–1,474) 556 (207–1,900)
Naïve 288 (74–1,173) 129 (74–1,173) 145 (27–939) 251 (27–939) 73 (74–1,173)
Central memory/transitional memory 307 (117–886) 421 (117–886) 634 (173–764) 630 (173–764) 370 (117–886)
Effector memory 53 (14–500) 174 (14–500) 118 (30–539) 410 (30–539) 90 (14–500)
Terminally differentiated 15 (0–87) 1.5 (0–87) 3.9 (0–219) 2.8 (0–219) 24 (0–87)
CD8+ 611 (160–1,103) 370 (160–1,103) 567 (202–1,571) 487 (202–1,571) 335 (160–1,103)
Naïve 356 (33–737) 192 (33–737) 19 (2–223) 14 (2–223) 30 (33–737)
Central memory/transitional memory 186 (54–424) 108 (54–424) 235 (42–321) 245 (42–321) 137 (54–424)
Effector memory 20 (2–515) 18 (2–515) 242 (11–925) 118 (11–925) 10 (2–515)
Effector CD27dim 1.1 (0–144) 1 (0–144) 27 (4–576) 11 (4–576) 5 (0–144)
Terminally differentiated 48 (1–273) 50 (1–273) 44 (0–905) 99 (0–905) 153 (1–273)
CD4− CD8− TCRγδ− 36 (5–79) 30 (5–79) 15 (2–27) 73 (2–27) 8.7 (5–79)
TCRγδ+ 160 (11–470) 33 (11–470) 80 (4–1,060) 57 (4–1,060) 156 (11–470)











Eosinophils 133 (17–2,353) 82 (17–2,353) 468 (40–508) 635 (40–508) 49 (17–2,353)
Basophils 36 (6–124) 43 (6–124) 42 (0–97) 162 (0–97) 22 (6–124)
Monocytes 413 (198–1,048) 486 (198–1,048) 438 (201–840) 1,480 (201–840) 363 (198–1,048)
Non-classical monocytes (CD16++) 91 (7–147) 109 (7–147) 188 (10–249) 409 (10–249) 99 (7–147)
Plasmacytoid DCs 16 (2.7–27) 6.6 (2.7–27) 8.8 (4–19) 7.9 (4–19) 5.2 (2.7–27)
Results expressed as absolute cell counts per µ of peripheral blood. Normal reference values are expressed as minimum and maximum values previously reported for age-matched
healthy donors (20, 21). Altered cell numbers are depicted in bold. mut, mutated allele; wt, wild type allele, PB, peripheral blood.
the first bp of the 7–8 intron. This mutation affected downstream
coding sequences corresponding to regions located between the
juxtamembrane and transmembrane domains of the CD4 gene.
As a result of the mutation, two frameshift deletions from
NM_000616: c.1157 onward were found in the mRNA/cDNA
sequences of both alleles of CD4. In line with these findings,
VEP analysis (36) predicted that the genomic alteration detected
(NC_000012.12: g6818420 G>A) would cause the observed
cDNA deletions due to modifications in the corresponding
splicing site. Identification of a 5 bp sequence at the end of
the minor deletion (NM_000616: c.1157_1185del), homologous
to the end sequence of wild type intron 7, suggests that in
this patient, a new alternative splicing variant might have
occurred 29 pb downstream of the mutation. This might reflect a
“repair” attempt to produce a functional CD4 protein capable of
anchoring CD4 to the cell surface membrane. However, further
studies are necessary to confirm this hypothesis and explain the
presence of the minor deletion variant identified here at the
mRNA level.
Further analysis of the patient’s parents and children
confirmed that the presence of the mutation identified in the
patient was an inherited germline mutation (NC_000012.12:
g6818420 G>A), as it was also found in heterozygosis in the
two parents and in her two children. Thus, in all four family
members two cDNAs were detected: a wild type and a truncated
(NM_000616: c.1157_1278del) CD4 cDNA. Most interestingly,
the presence of the mutation in heterozygosis resulted in
decreased levels of CD4 protein expression in all CD4+ cell
types to around half of normal CD4 levels per cell. This further
confirms the direct association between the (NC_000012.12:
g6818420 G>A) CD4 gene mutation and CD4 expression levels
on immune cells in the blood for a codominant gene expression
profile. In contrast, this or other CD4 gene mutations were not
found in the brother of the patient, who only showed wild type
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TABLE 4 | In vitro cytokine production by PB T-cells of the patient and her relatives after polyclonal (PMA + ionomycin) and after antigen-specific stimulation (whole CMV
lysate).
Cytokine Subset Healthy adults (n = 5) Patient Daughter Son Mother Father Brother
POLYCLONAL STIMULATION (PMA + IONOMYCIN)
IFNγ CD8+ T-cells 26–67% 39% 26% 32% 81% 76% 76%
CD4+ T-cells 19–32% 44%* 22% 45% 38% 27% 34%
IL-4/IL-5 CD8+ T-cells 0.1–0.3% 0.5% 0.1% 0.3% 0.4% 0.1% 0.6%
CD4+ T-cells 1.6–2.9% 4%* 1.1% 2.6% 1.7% 1% 2.1%
IL-17A/IL-17F CD8+ T-cells 0.2–1.3% 5% 0.7% 3.2% 6.3% 9% 5.7%
CD4+ T-cells 1.4–2.5% 5%* 3% 14% 5.8% 6% 7.2%
ANTIGEN-SPECIFIC STIMULATION (CMV)
IFNγ CD8+ T-cells 0.3–0.7% 0.8% 0% 0.2% 1% 2.9% 0.3%
CD4+ T-cells 0.5–5% 0.4%* 0.4% 4.8% 1.6% 1.6% 1%
IL-4/IL-5 CD8+ T-cells 0–0% 0% 0% 0% 0% 0% 0.6%
CD4+ T-cells 0–0.2% 0.1%* 0% 0% 0% 0.2% 0%
IL-17A/IL-17F CD8+ T-cells 0–0% 0% 0% 0% 0% 0% 0.05%
CD4+ T-cells 0–0% 0.4%* 0% 0% 0% 0% 0.08%
Results expressed as percentage of cells positive for each cytokine in CD8+, CD4+ T-cells and double-negative T-cells (DNTs). *Results from double CD4− CD8− TCRγδ− T-cells.
cDNA and normal levels of cellular CD4 expression in blood
T-cells, monocytes, and DCs.
Despite no cases of CD4null mutation having been previously
reported in humans, the immunological consequences of a lack
of CD4 expression have been extensively analyzed in CD4
KO mice (13, 14, 41). Although it is well-established that
CD4 plays an important role in differentiation, maturation,
and the functionality of MHC/HLA class II–restricted T-
lymphocytes, previous studies in CD4 KO mice indicate
that this molecule is not absolutely required for (i) positive
selection of T-cells (41, 42) and (ii) the effector function
of MHC/HLA class II–restricted helper T-cells (13, 14, 41,
43). Thus, CD4 KO mice are apparently healthy, fertile, and
indistinguishable from wild type littermates on gross physical
inspection (13). In fact, except for a lack of CD4+ T-cells,
defects in the CD4 gene did not show a major impact on
leukocyte production and differentiation, with normal CD8+
T-cell, B-cell, and myeloid cell counts in CD4 KO mice (13,
14, 41). Here, we confirmed that, also in our patient, apart
from a lack of CD4+ T-cells and CD4+ innate cells, the CD4
mutation was associated with overall normal lymphocyte and
myeloid cell counts, including normal monocyte and DC counts
and functionality.
Failure to control infections has been observed in mice
(and humans) that lack CD4+ T-cells, after sustained CD4+ T-
cell depletion, or due to MHC/HLA class II defects (35, 44).
In contrast, CD4 KO mice are able to control infections at
levels similar to wild type animals for virtually all pathogens
investigated, including viral (13, 45–47), bacterial (43, 48, 49),
and parasite (14) infections. The ability of CD4 KO mice
to mount normal immune responses has been consistently
associated with a subset of MHC/HLA class II–restricted T-
cells that emerge from the thymus as DN TCRγδ− TCRαβ+
T-cells that fully replace the functional role of conventional
CD4+ T-helper cells (13, 14, 41, 43). These DN T-cells are
expanded in PB of CD4 KO mice (10–20% of the T-cell pool
in blood) (13) and other immune tissues, including the spleen
(14), lymph nodes (13, 41), and mucosa (50). Interestingly,
expanded DN T-cells in CD4 KO mice have been shown to
efficiently help to mount potent cytotoxic and humoral immune
responses, including those involving immunoglobulin class-
switch recombination (13, 41). Similar to CD4 KO mice, our
patient also showed an expansion of DN T-cells. Like their CD4
KO mouse counterpart, DN T-cells from the CD4null patient
here reported were capable of producing Th1, Th2, and Th17
cytokines at similar levels to those of normal conventional
CD4+ T-cells, in response to both unspecific and specific
stimuli requiring antigen presentation. In addition, they showed
identical expression profiles for Th surrogate markers, including
markers of Tregs, TFH, Th1, Th2, Th17, and Th1/Th17,
compared to age-matched normal CD4+ blood T-cells (26, 27)
(Botafogo et al., submitted). Despite this, the patient persistently
showed abnormally increased naïve CD8 T-cell numbers in the
blood with an inverted helper/cytotoxic T-cell ratio (0.6 for
total T-cells, 0.3 for naïve T-cells). Previous studies in mice
have shown that positive selection of CD4+ T-helper thymocytes
is around fivefold less efficient in the absence of CD4, due
to inefficient positive selection (42). These results suggest that
the lack of CD4 might provide a competitive advantage to
the CD8 lineage in the thymus, consistent with the increased
naïve CD8 T-cell numbers found in our patient. However, the
clonal diversity of DN helper T-cells was not affected, and,
like in CD4 KO mice (14), a polyclonal TCRVβ repertoire
was found among DN T-cells, similar to that of conventional
CD4+ helper T-cells. Such a polyclonal DN T-cell repertoire as
found in our CD4-deficient patient (and in CD4 KO mice) is
different from the typically restricted TCRVβ repertoire observed
in DN T-cells from healthy mice and humans (51) and from
autoimmune lymphoproliferative syndrome (ALPS) patients
(52), which usually contain expanded clones of MHC/HLA class
I–related T-cells. Of note, the lack of CD4 expression by DN
T-cells did not appear to significantly affect differentiation of
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cytotoxic T-cells, since normal antigen-experienced memory and
effector CD8+ T-cell and NK-cell counts associated with normal
expression profiles of cytolytic enzymes were observed in PB
except for borderline low TCRαβ+ CD8+ CD27lo effector T-
cells. Likewise, we did not observe any significant global effect
of the CD4 defect on the humoral immune response, as normal
(or even slightly increased) IgM, IgG1−3, and IgA1−2 memory
B-cell and plasmablast subset counts (associated with normal or
slightly increased serum antibody levels) were observed in our
patient. These findings suggest that DN T-cells from our patient
are also capable of supporting T-cell–dependent B-cell activation
and immunoglobulin isotype switching, as previously reported
for CD4 KO mice (41). Altogether, these results support the
notion that CD4 is dispensable for commitment of thymocyte
precursors to the helper T-cell lineage as long as the affinity
threshold for positive selection is sustained (53). At the same
time, they strongly argue against an essential role for CD4
in delivering a unique instructional signal for T-helper cell
lineage commitment. Although no cell surface membrane or
intracytoplasmic expression of CD4 protein was detected in
our patient, we found expression of truncated CD4 mRNA
and normal soluble CD4 plasma levels evaluated with MoAb
against extracellular domains of the protein. Further studies
would be necessary to characterize the amino acid sequence
of this soluble CD4 protein. Altogether, these findings support
the notion that (TCRγδ− TCRαβ+) DN T-cells committed to
the CD4 T-cell lineage/compartment are produced even in the
absence of CD4 expression. These cells may overall contribute
to maintaining normal immune surveillance based on otherwise
normal primary and secondary immune responses associated
with fast clearance of infection, against both intracellular and
extracellular pathogens, as previously observed in KO mice (13,
14, 43, 45, 49). However, a few studies have previously reported
a decreased ability of these DN T-cells to induce long-term
cytotoxic memory cells and prevent viral persistence in specific
situations (44, 54, 55), which might contribute to explaining the
recurrent skin lesions observed in our patient. Further studies
are necessary to elucidate the precise mechanisms involved
in the overall higher naïve and memory B-cell counts and
the presence of potentially dysfunctional helper and regulatory
antigen-associated/specific DN T-cells.
While the function of CD4 on T-cells has been characterized
in detail, the functional role of CD4 on human monocytes is
much less understood (56). At present, it is well-established that
monocytes do not express lck (an src-family kinase) that interacts
with the intracellular domain of CD4 in T-cells. Thus, it has
been suggested that CD4 activation via interaction with MCH-
II might contribute to cytokine production and differentiation
of human blood cMo into ncMo and macrophages (56, 57). In
our patient, the lack of CD4 expression did not show a significant
impact either on the PB counts of DCs, cMo, and ncMo or on
the profile and amount of inflammatory cytokines produced by
these cells after in vitro stimulation vs. age-matched controls
(26, 39). However, further functional studies are still required
to determine the impact of this mutation on the distinct subsets
of monocytes’ functionality, including their susceptibility to be
infected by HIV.
In fact, the most striking sign of immunodeficiency found in
our patient is the presence of extensive verrucous lesions since
she was 10 years-old, which were resistant to treatment with
topical keratolytic agents, cryosurgery, and excision. Despite no
CD4 gene defect having been previously reported in humans,
several case reports have previously described the association of
persistent idiopathic CD4+ T-cell lymphopenia, in the absence
of infection with HIV 1 or HTLV-1/2, and/or of a well-
defined (primary or secondary) immunodeficiency disease, with
recalcitrant warts and generalized verrucosis (58–64). Thus,
more than half of idiopathic CD4+ T-cell lymphopenia cases
present with mucocutaneous lesions (15, 16). Disseminated warts
have also been frequently found in several autosomal recessive
genetic defects that present with CD4 lymphopenia (e.g., RAG1,
RHOH, MST1, CORO1A, DOCK8) (17–19). However, none of
these genetic defects are specific for the CD4 T-cell lineage,
and Idiopathic CD4 lymphopenia patients typically display
additional clinical and immunological features in common
with other combined immunodeficiencies (65–68). In fact,
detailed analysis of idiopathic CD4 lymphopenia cases reported
in the literature shows that many of them are not selective
CD4 T-cell deficiencies, since they commonly show additional
immunologic defects including decreased CD8+ T-cell, B-cell,
and NK-cell counts in PB and/or low immunoglobulin levels
(15, 16). In these patients, the presence of such immune
alterations other than CD4 lymphopenia is associated with a
higher risk of severe opportunistic infections and a greater
mortality (15, 16). In contrast, patients with selective depletion
of CD4+ T-cells but normal CD8+ T-cell and B-cell counts, as
well as normal serum antibody levels, have been reported to
display clinical manifestations restricted to cutaneous or genital
infections (69, 70), in the absence of a broader susceptibility to
more severe infections. Further studies are therefore required
to understand the apparently close association between the
lack of expression of CD4 and persistent and recurrent
warts, which points out a still-unraveled (critical) role of the
CD4 protein.
In summary, here we report for the first time ever a patient
carrying a CD4 gene mutation that translates into complete
abrogation of CD4 expression in multiple lymphoid and
myeloid cell lineages, associated with recurrent, treatment-
refractory warts in both hands and feet, in the absence
of other clinically relevant manifestations of disease. In
contrast to individuals depleted in CD4+ T-cells due to an
external agent (e.g., HIV infection) or an associated combined
immunodeficiency involving other immune cell compartments,
defective CD4 expression was associated in our patient with
milder immunological and clinical manifestations, except for
refractory and recurrent skin lesions. This unique case provides
insight about the role of CD4 in human T-cell differentiation,
T-cell selection in the thymus, and effector T-helper and Treg
functions that supports previous observations in CD4 KO mice.
Altogether, our findings suggest that although CD4 contributes
to MHC/HLA class II binding and signal transduction, it
is not essential to generate MHC/HLA-II–restricted helper
T-cells and T-helper–dependent cytotoxic and humoral
immune responses.
Frontiers in Immunology | www.frontiersin.org 10 November 2019 | Volume 10 | Article 2502
Fernandes et al. Complete Multilineage CD4 Expression Defect
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, to
any qualified researcher.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Comité de Ética de la Investigación con
medicamentos. del area de Salud de Salamanca. Written
informed consent to participate in this study was provided by the
participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
RF, MP-A, AO, and EF contributed to the conception
and design of the study. RF, ICo, and EF collected and
analyzed the clinical and serological information of the
patient and relatives. MP-A, EB, ICr, JA, VB, and AP
performed the flow cytometry data acquisition and data
analysis. MJ-A and EB performed the molecular biology
data acquisition and data analysis. RF, MP-A, JA, AP, JD,
AO, and EF critically reviewed the data. RF, MP-A, EB,
MJ-A, AO, and EF wrote the manuscript. All authors
contributed to manuscript revision and read and approved the
submitted version.
FUNDING
EB was supported by a grant from the Junta de Castilla y León
(Fondo Social Europeo, ORDEN EDU/346/2013, Valladolid,
Spain). This work was supported by: the CB16/12/00400 grant
(CIBERONC, Instituto de Salud Carlos III, Ministerio de
Economía y Competitividad, Madrid, Spain and FONDOS
FEDER), the FIS PI12/00905-FEDER grant (Fondo de
Investigación Sanitaria of Instituto de Salud Carlos III,
Madrid, Spain), and a grant from Fundación Mutua Madrileña
(Madrid, Spain).
SUPPLEMENTARY MATERIAL




1. Janeway CA Jr. The T cell receptor as a multicomponent signaling machine:
CD4/CD8 coreceptors and T cell activation. Annu Rev Immunol. (1992)
10:645–54. doi: 10.1146/annurev.iy.10.040192.003241
2. Zamoyska R. CD4 and CD8: Modulators of T-cell receptor recognition of
antigen and of immune responses? Curr Opin Immunol. (1998) 10:82–7.
doi: 10.1016/s0952-7915(98)80036-8
3. Li Y, Yin Y, Mariuzza RA. Structural and biophysical insights into the
role of CD4 and CD8 in T cell activation. Front Immunol. (2013) 4:206.
doi: 10.3389/fimmu.2013.00206
4. Singer A, Bosselut R. CD4/CD8 coreceptors in thymocyte development,
selection, and lineage commitment: analysis of the CD4/CD8 lineage decision.
Adv Immunol. (2004) 83:91–131. doi: 10.1016/s0065-2776(04)83003-7
5. Fuller TC, Trevithick JE, Fuller AA, Colvin RB, Cosimi AB, Kung PC.
Antigenic polymorphism of the T4 differentiation antigen expressed on
human T helper/inducer lymphocytes. Hum Immunol. (1984) 9:89–102.
doi: 10.1016/0198-8859(84)90031-4
6. Lederman S, DeMartino JA, Daugherty BL, Foeldvari I, Yellin MJ, Cleary AM,
et al. A single amino acid substitution in a common African allele of the CD4
molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol.
(1991) 28:1171–81. doi: 10.1016/0161-5890(91)90003-3
7. Laing KJ, Zou JJ, Purcell MK, Phillips R, Secombes CJ, Hansen JD. Evolution
of the CD4 family: teleost fish possess two divergent forms of CD4 in
addition to lymphocyte activationgene-3. J Immunol. (2006) 177:3939–51.
doi: 10.4049/jimmunol.177.6.3939
8. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of
T-cell differentiation: human memory T-cell subsets. Eur J Immunol. (2013)
43:2797–809. doi: 10.1002/eji.201343751
9. Sallusto F. Heterogeneity of Human CD4+T cells against microbes.Annu Rev
Immunol. (2016) 34:317–34. doi: 10.1146/annurev-immunol-032414-112056
10. Caramalho Í, Nunes-Cabaço H, Foxall RB, Sousa AE. Regulatory T-
cell development in the human thymus. Front Immunol. (2015) 6:395.
doi: 10.3389/fimmu.2015.00395
11. Almeida J, Bueno C, Algueró MC, Sanchez ML, de Santiago M, Escribano
L, et al. Comparative analysis of the morphological, cytochemical,
immunophenotypical, and functional characteristics of normal human
peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells,
CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol. (2001)
100:325–38. doi: 10.1006/clim.2001.5072
12. Basch RS, Kouri YH, Karpatkin S. Expression of CD4 by human
megakaryocytes. Proc Natl Acad Sci USA. (1990) 87:8085–9.
doi: 10.1073/pnas.87.20.8085
13. Rahemtulla A, Fung-Leung WP, Schilham MW, Kündig TM, Sambhara SR,
Narendran A, et al. Normal development and function of CD8+ cells but
markedly decreased helper cell activity in mice lacking CD4. Nature. (1991)
353:180–4. doi: 10.1038/353180a0
14. Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N. Helper T cells
without CD4: control of leishmaniasis in CD4-deficient mice. Science. (1993)
261:1448–51. doi: 10.1126/science.8367726
15. Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, et al.
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.
Blood. (2008) 112:287–94. doi: 10.1182/blood-2007-12-127878
16. Régent A, Autran B, Carcelain G, Cheynier R, Terrier B, Charmeteau-De
Muylder B, et al. Idiopathic CD4 lymphocytopenia: clinical and immunologic
characteristics and follow-up of 40 patients. Medicine. (2014) 93:61–72.
doi: 10.1097/MD.0000000000000017
17. Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF,
Douek DC, et al. Second messenger role for Mg2+ revealed by human
T-cell immunodeficiency. Nature. (2011) 475:471–6. doi: 10.1038/nature
10246
18. Kuijpers TW, Ijspeert H, van leeuwen EM, Jansen MH, Hazenberg MD,
Weijer KC, et al. Idiopathic CD4+ T lymphopenia without autoimmunity
or granulomatous disease in the slipstream of rag mutations. Blood. (2011)
117:5892–6. doi: 10.1182/blood-2011-01-329052
19. de Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E,
et al. Epidermodysplasia verruciformis: inborn errors of immunity
to human beta-papillomaviruses. Front Microbiol. (2018) 9:1222.
doi: 10.3389/fmicb.2018.01222
20. Republic of Portugal – Directorate-General of Health (DGS). Programa
Nacional para a Eliminação do Sarampo [National Programme for Measles
Elimination]. Lisbon: DGS (Portuguese). Available online at: https://www.
dgs.pt/documentose-publicacoes/programa-nacional-de-eliminacao-do-
sarampojpg.aspx
Frontiers in Immunology | www.frontiersin.org 11 November 2019 | Volume 10 | Article 2502
Fernandes et al. Complete Multilineage CD4 Expression Defect
21. Goncalves G, De Araujo A, Monteiro Cardoso ML. Outbreak of mumps
associated with poor vaccine efficacy – Oporto Portugal 1996. Euro Surveill.
(1998) 3:119–21. doi: 10.2807/esm.03.12.00101-en
22. Maia C, Fonseca J, Carvalho I, Santos H, Moreira D. Clinical and
epidemiological study of complicated infection by varicella-zoster virus in the
pediatric age. Acta Med Port. (2015) 28:741–8. doi: 10.20344/amp.6264
23. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O,
Böttcher S, et al. Next Generation Flow for highly sensitive and standardized
detection of minimal residual disease in multiple myeloma. Leukemia. (2017)
31:2094–103. doi: 10.1038/leu.2017.29
24. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Böttcher
S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument
settings and immunophenotyping protocols. Leukemia. (2012) 26:1986–2010.
doi: 10.1038/leu.2012.122
25. van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden
VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized
n-dimensional flow cytometric immunophenotyping of normal, reactive
and malignant leukocytes. Leukemia. (2012) 26:1908–75. doi: 10.1038/leu.
2012.120
26. Van der Burg M, Kalina T, Perez-Andres M, VLkova M, Lopez-Granados
E, Blanco E et al. The EuroFlow PID orientation tube for flow cytometric
diagnostic screening of primary immunodeficiencies of the lymphoid system.
Front Immunol. (2019) 10:246. doi: 10.3389/fimmu.2019.00246
27. van Dongen JJM, van der Burg M, Kalina T, Perez-Andres M, Mejstrikova
E, Vlkova M, et al. EuroFlow based flowcytometric diagnostic screening and
classification of primary immunodeficiencies of the lymphoid system. Front
Immunol. (2019) 10:1271. doi: 10.3389/fimmu.2019.01271
28. Blanco E, Perez-Andres M, Sanoja-Flores L, Wentink M, Pelak O, Martín-
Ayuso M, et al. Selection and validation of antibody clones against IgG and
IgA subclasses in switched memory B-cells and plasma cells. J Immunol
Methods. (2017). doi: 10.1016/j.jim.2017.09.008. [Epub ahead of print].
29. Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G,
Galende J, et al. Characterization of bone marrow T cells in monoclonal
gammopathy of undetermined significance, multiple myeloma, and plasma
cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells
demonstrating a squed TCR-Vbeta repertoire. Cancer. (2006) 106:1296–305.
doi: 10.1002/cncr.21746
30. Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-
specific cytokine assays for CD4+ T cells. Cytometry. (2000) 40:60–8.
doi: 10.1002/(SICI)1097-0320(20000501)40:1<60::AID-CYTO8>3.0.CO;2-J
31. Rodríguez-Caballero A, García-Montero AC, Bueno C, Almeida J, Varro R,
Chen R, et al. A new simple whole blood flow cytometry-based method
for simultaneous identification of activated cells and quantitative evaluation
of cytokines released during activation. Lab Invest. (2004) 84:1387–98.
doi: 10.1038/labinvest.3700162
32. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC. Epitopes of
the CD4 antigen and HIV infection. Science. (1986) 234:1120–3.
doi: 10.1126/science.2430333
33. Sattentau QJ, Arthos J, Deen K, Hanna N, Healey D, Beverley PC, et al.
Structural analysis of the human immunodeficiency virus-binding domain of
CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp
Med. (1989) 170:1319–34. doi: 10.1084/jem.170.4.1319
34. Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, et al. A
specific CD4 epitope bound by tregalizumab mediates activation of regulatory
T cells by a unique signaling pathway. Immunol Cell Biol. (2015) 93:396–405.
doi: 10.1038/icb.2014.102
35. Hanna S, Etzioni A. MHC class I and II deficiencies. J Allergy
Clin Immunol. (2014) 134:269–75. doi: 10.1016/j.jaci.2014.
06.001
36. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A,
et al. The ensemble variant effect predictor. Genome Biol. (2016) 17:122.
doi: 10.1186/s13059-016-0974-4
37. van den Beemd R, Boor PP, van Lochem EG, Hop WC, Langerak
AW, Wolvers-Tettero IL, et al. Flow cytometric analysis of the
Vbeta repertoire in healthy controls. Cytometry. (2000) 40:336–45.
doi: 10.1002/1097-0320(20000801)40:4<336::AID-CYTO9>3.0.CO;2-0
38. Blanco E, Pérez-Andrés M, Arriba-Méndez S, Contreras-Sanfeliciano T,
Criado I, Pelak O, et al. Age-associated distribution of normal B-cell and
plasma cell subsets in peripheral blood. J Allergy Clin Immunol. (2018)
141:2208–19.e16. doi: 10.1016/j.jaci.2018.02.017
39. Damasceno D, Teodosio C, van den Bossche WBL, Perez-Andres M,
Arriba-Méndez S, Muñoz-Bellvis L, et al. Distribution of subsets of blood
monocytic cells throughout life. J Allergy Clin Immunol. (2019) 144:320–3.e6.
doi: 10.1016/j.jaci.2019.02.030
40. Martín-Ayuso M, Almeida J, Pérez-Andrés M, Cuello R, Galende
J, González-Fraile MI, et al. Peripheral blood dendritic cell subsets
from patients with monoclonal gammopathies show an abnormal
distribution and are functionally impaired. Oncologist. (2008) 13:82–92.
doi: 10.1634/theoncologist.2007-0127
41. Rahemtulla A, Kündig TM, Narendran A, Bachmann MF, Julius M,
Paige CJ, et al. Class II major histocompatibility complex-restricted T
cell function in CD4-deficient mice. Eur J Immunol. (1994) 24:2213–8.
doi: 10.1002/eji.1830240942
42. Strong J, Wang Q, Killeen N. Impaired survival of T helper cells
in the absence of CD4. Proc Natl Acad Sci USA. (2001) 98:2566–71.
doi: 10.1073/pnas.051329698
43. Derrick SC, Evering TH, Sambandamurthy VK, Jalapathy KV, Hsu T,
Chen B, et al. Characterization of the protective T-cell response generated
in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis
vaccine. Immunology. (2007) 120:192–206. doi: 10.1111/j.1365-2567.2006.
02491.x
44. Trautmann T, Kozik JH, Carambia A, Richter K, Lischke T, Schwinge D,
et al. CD4+ T-cell help is required for effective CD8+ T cell-mediated
resolution of acute viral hepatitis in mice. PLoS ONE. (2014) 9:e86348.
doi: 10.1371/journal.pone.0086348
45. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL. CD4-
deficient mice have reduced levels of memory cytotoxic T lymphocytes after
immunization and show diminished resistance to subsequent virus challenge.
J Virol. (1996) 70:1072–9.
46. Moretto M, Casciotti L, Durell B, Khan IA. Lack of CD4(+) T
cells does not affect induction of CD8(+) T-cell immunity against
Encephalitozoon cuniculi infection. Infect Immun. (2000) 68:6223–32.
doi: 10.1128/IAI.68.11.6223-6232.2000
47. Fang M, Remakus S, Roscoe F, Ma X, Sigal LJ. CD4+ T cell help
is dispensable for protective CD8+ T cell memory against mousepox
virus following vaccinia virus immunization. J Virol. (2015) 89:776–83.
doi: 10.1128/jvi.02176-14
48. Pearce EL, Shedlock DJ, Shen H. Functional characterization of MHC class II-
restricted CD8+CD4- and CD8-CD4- T cell responses to infection in CD4-/-
mice. J Immunol. (2004) 173:2494–9. doi: 10.4049/jimmunol.173.4.2494
49. Wang J, Santosuosso M, Ngai P, Zganiacz A, Xing Z. Activation of
CD8T Cells by mycobacterial vaccination protects against pulmonary
tuberculosis in the absence of CD4T Cells. J Immunol. (2004) 173:4590–7.
doi: 10.4049/jimmunol.173.7.4590
50. Hörnquist CE, Ekman L, Grdic KD, Schön K, Lycke NY. Paradoxical IgA
immunity in CD4-Deficient mice. J Immunol. (1995) 155:2877-87.
51. Niehues T, Gulwani-Akolkar B, Akolkar PN, Tax W, Silver J. Unique
phenotype and distinct TCR V beta repertoire in human peripheral blood
alpha beta TCR+, CD4-, and CD8-double negative T cells. J Immunol.
(1994) 152:1072–81.
52. Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer
A, et al. Human TCR alpha/beta+ CD4-CD8- double-negative T cells in
patients with autoimmune lymphoproliferative syndrome express restricted
Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol.
(2008) 181:440–8. doi: 10.4049/jimmunol.181.1.440
53. Kao H, Allen PM. An antagonist peptide mediates positive selection and CD4
lineage commitment of MHC class II–restricted T cells in the absence of CD4.
J Exp Med. (2005) 201:149–58. doi: 10.1084/jem.20041574
54. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW,
Zinkernagel RM. Enhanced establishment of a virus carrier state in adult
CD4+ T-cell-deficient mice. J Virol. (1994) 68:4700–4.
55. Shedlock DJ, Shen H. Requirement for CD4T cell help in
generating functional CD8T cell memory. Science. (2003) 300:337–9.
doi: 10.1126/science.1082305
56. Glatzová D, Cebecauer M. Dual Role of CD4 in peripheral T lymphocytes.
Front Immunol. (2019) 10:618. doi: 10.3389/fimmu.2019.00618
Frontiers in Immunology | www.frontiersin.org 12 November 2019 | Volume 10 | Article 2502
Fernandes et al. Complete Multilineage CD4 Expression Defect
57. Zhen A, Krutzik SR, Levin BR, Kasparian S, Zack JA, Kitchen SG. CD4 ligation
on human bloodmonocytes triggersmacrophage differentiation and enhances
HIV infection. J Virol. (2014) 88:9934–46. doi: 10.1128/JVI.00616-14
58. Manchado LP, Ruiz de Morales JM, Ruiz Gonzalez I, Rodriguez Prieto MA.
Cutaneous infections by papillomavirus, herpes zoster, and Candida albicans
as the only manifestation of idiopathic CD4+ T lymphocytopenia. Int J
Dermatol. (1999) 38:119–21. doi: 10.1046/j.1365-4362.1999.00364.x
59. Van Wagoner JA, Khan DA. Selective CD4+ T cell lymphocytopenia and
recalcitrant warts in an 8-year-old child.Ann Allergy Astham Immunol. (2001)
87:373–78. doi: 10.1016/S1081-1206(10)62917-1
60. Stetson CL, Rapini RP, Tyring SK, Kimbrough RC. CD4+ T
lymphocytopenia with disseminated HPV. J Cutan Pathol. (2002) 29:502–05.
doi: 10.1034/j.1600-0560.2002.290809.x
61. Fischer LA, Norgaard A, Permin H, Ryder LP, Marquart H, Svejgaard
A, et al. Multiple flat warts associated with idiopathic CD4-
positive T lymphocytopenia. J Am Acad Dermatol. (2008) 58:S37–8.
doi: 10.1016/j.jaad.2006.04.026
62. Ladoyanni E, North J, Tan CY. Idiopathic CD4+ T-cell lymphocytopaenia
associated with recalcitrant viral warts and squamous malignancy. Acta Derm
Venereol. (2008) 87:76–7. doi: 10.2340/00015555-0150
63. Alisjahbana B, Dinata R, Sutedja E, Suryahudaya I, Soedjana H, Hidajat
NN, et al. Disfiguring generalized verrucosis in an Indonesian man
with idiopathic CD4 lymphopenia. Arch Dermatol. (2010) 146:69–73.
doi: 10.1001/archdermatol.2009.330
64. Cheung L, Weinstein M. Idiopathic CD4 T-Cell Lymphocytopenia: a case
report of a young boy with recalcitrant warts. J Cutan Med Surg. (2016)
20:470–3. doi: 10.1177/1203475416638045
65. Crequer A, Picard C, Patin E, D’Amico A, Abhyankar A, Munzer M, et al.
Inherited MST1 deficiency underlies susceptibility to EV-HPV infections.
PLoS ONE. (2012) 7:e44010. doi: 10.1371/journal.pone.0044010
66. Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, et al.
Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV
infections. J Clin Invest. (2012) 122:3239–47. doi: 10.1172/JCI62949
67. Stray-Pedersen A, Jouanguy E, Crequer A, Bertuch AA, Brown BS,
Jhangiani SN, et al. Compound heterozygous CORO1A mutations in siblings
with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia
verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid
leprosy. J Clin Immunol. (2014) 34:871–90. doi: 10.1007/s10875-014-
0074-8
68. Tahiat A, Badran YR, Chou J, Cangemi B, Lefranc G, Labgaa ZM,
et al. Epidermodysplasia verruciformis as a manifestation of ARTEMIS
deficiency in a young adult. J Allergy Clin Immunol. (2017) 139:372–5.e4.
doi: 10.1016/j.jaci.2016.07.024
69. Borgogna C, Landini MM, Lanfredini S, Doorbar J, Bouwes Bavinck
JN, et al. Characterization of skin lesions induced by skin-tropic
α- and β-papillomaviruses in a patient with epidermodysplasia
verruciformis. Br J Dermatol. (2014) 171:1550–4. doi: 10.1111/bjd.
13156
70. Landini MM, Borgogna C, Peretti A, Colombo E, Zavattaro E, Boldorini
R, et al. α- and β-Papillomavirus infection in a young patient with
an unclassified primary T-cell immunodeficiency and multiple mucosal
and cutaneous lesions. J Am Acad Dermatol. (2014) 71:108–15.e1.
doi: 10.1016/j.jaad.2014.01.859
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Fernandes, Perez-Andres, Blanco, Jara-Acevedo, Criado, Almeida,
Botafogo, Coutinho, Paiva, van Dongen, Orfao and Faria. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 13 November 2019 | Volume 10 | Article 2502
